Description
DOTA-LM3 is a cyclized, DOTA-containing peptide designed as a potent somatostatin receptor (SSTR) antagonist. Its carefully engineered sequence (DOTA-[p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH?]) imparts high receptor affinity and stability. Equipped with a DOTA chelator, it can be radiolabeled (e.g., with ??Ga or ¹??Lu) to create tumor-targeting imaging or therapeutic agents. Used extensively in peptide receptor radionuclide therapy (PRRT), DOTA-LM3 shows favorable biodistribution, strong tumor uptake and retention, and promising applicability in SSTR-negative liver metastases and pancreatic neuroendocrine tumors. Manufactured under GMP oversight with ?99.37% purity, this peptide ensures reproducibility for advanced oncology and receptor-targeting studies.
Product Category
Radiolabeled Peptide Tumor Tracers — specialized peptides for oncological imaging and therapy, designed to be labeled with radioactive isotopes for SSTR-targeted applications.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | DOTA-LM3 |
| Synonyms | SSTR antagonist peptide with DOTA chelator |
| CAS Number | 1192362-32-5 |
| Purity | ?99.37% |
| Classification | Somatostatin receptor (SSTR) antagonist with radiolabeling capability |
| Sequence | DOTA-[p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carba)-Lys-Thr-Cys)D-Tyr-NH?] |
| Molecular Formula | C??H??ClN??O??S? |
| Molecular Weight | ?1,550 Da |
| Appearance | White to off-white powder |
| Solubility | Soluble in aqueous buffers and DMSO; sonication recommended |
| Storage | Store lyophilized at –20 °C; avoid light and moisture |
| Stability (lyophilized) | Up to 3 years |
| GMP Compliance | Yes — GMP-certified manufacturer |
Mechanism of Action & Research Applications
DOTA-LM3 functions as a high-affinity antagonist to somatostatin receptors, enabling it to bind to receptor-overexpressing tumors and internalize when radiolabeled. Commonly tagged with radioisotopes such as ??Ga or ¹??Lu, it serves as a precision agent in diagnostic PET imaging or therapeutic PRRT. Preclinical models demonstrate excellent tumor localization, robust retention, and favorable biodistribution—particularly beneficial in tumors unresponsive to traditional SSTR agonists. These properties make it a powerful tool to probe both imaging and therapeutic efficacy in oncology.
Side Effects & Considerations (For Research Context Only)
As a research-only peptide, DOTA-LM3 does not present human-use data. In vivo evaluations reveal minimal off-target tissue uptake beyond renal and splenic clearance—typical of radiolabeled peptides. Researchers should be mindful of potential nephrotoxicity in radioactive studies and evaluate dosage and radiation exposure accordingly.
Logistics Transportation
All shipments are insured and tracked to ensure safe and prompt delivery. In case of any loss, detention, or damage during transit, we provide 100% compensation. Your peace of mind is our priority.
Disclaimer
DOTA-LM3 is intended solely for laboratory research use. It is not approved for clinical, therapeutic, or human/animal diagnostic purposes.


Reviews
There are no reviews yet.